Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.

New strategies and perspectives on managing IgA nephropathy

Open access
Selvaskandan, Haresh, Cheung, Chee Kay, Muto, Masahiro, Barratt, Jonathan · 2019 · Clinical and Experimental Nephrology

Abstract

IgA nephropathy is an inflammatory renal disease characterised by the deposition of IgA in the glomerular mesangium and is the most commonly reported primary glomerulonephritis worldwide. Thirty to forty percent of patients with the disease develop progressive renal function decline, requiring renal replacement therapy within two decades of diagnosis. Despite this, accurate individual risk stratification at diagnosis and predicting treatment response remains a challenge. Furthermore, there are currently no disease specific treatments currently licensed to treat the condition due to long standing challenges in the nature and prevalence of the disease. Despite this, there have been exciting recent advances in the field that may represent paradigm shifts in the way IgA nephropathy is managed in the near future. In this review, we explore the evidence base informing current approaches to management and explore new strategies and future directions in the diagnosis and management of IgA nephropathy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10157-019-01700-1

Cites

110 of 110 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Targets of novel/repurposed drugs. Target 1: B-lymphocyte activation results in the production IgA1 poorly O-glycosylated at the hinge region (gd-IgA1, highlighted in red). This results in the generation of auto-antibodies, which leads to the formation of immune complexes. The deposition of immune complexes in the mesangium will lead to varying degrees of inflammation and fibrosis. Atacicept, blisibimod, TRF-budesonide, bortezomib and microbiome modulation can modulate B-lymphocyte activity, which may theoretically lead to a reduction in the production of Gd-IgA1, the auto-antibodies and circulating immune complexes. Target 2: Acthar, avacopan, OMS721 and LNP023 all act in the kidney to suppress local inflammation and subsequent fibrosis, dampening the downstream consequences of immune complex deposition. Fostamatinib acts both at the level of the B-cell and directly in the kidney reducing the inflammatory response to IgA deposition. IgA1 proteases are capable of digesting both circulating and deposited IgA and IgA immune complexes
Fig. 1 Targets of novel/repurposed drugs. Target 1: B-lymphocyte activation results in the production IgA1 poorly O-glycosylated at the hinge region (gd-IgA1, highlighted in red). This results in the generation of auto-antibodies, which leads to the formation of immune complexes. The deposition of immune complexes in the mesangium will lead to varying degrees of inflammation and fibrosis. Atacicept, blisibimod, TRF-budesonide, bortezomib and microbiome modulation can modulate B-lymphocyte activity, which may theoretically lead to a reduction in the production of Gd-IgA1, the auto-antibodies and circulating immune complexes. Target 2: Acthar, avacopan, OMS721 and LNP023 all act in the kidney to suppress local inflammation and subsequent fibrosis, dampening the downstream consequences of immune complex deposition. Fostamatinib acts both at the level of the B-cell and directly in the kidney reducing the inflammatory response to IgA deposition. IgA1 proteases are capable of digesting both circulating and deposited IgA and IgA immune complexesCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 110 references

Research works printed but not linked: 1

  1. Edsbäcker S, Wollmer P, Nilsson A, Nillson M. Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsules. Gastroenterology. 1993;104:A695.

Cited by

See all 83

Metadata

Authors
Selvaskandan, H., Cheung, C. K., Muto, M., & Barratt, J.
Affiliations
University of Leicester (GB)
Corresponding author
Barratt, Jonathan
Venue
Clinical and Experimental Nephrology
Published
2019-02-13
Volume
23
Issue
5
Pages
577-588
ISSN
  • 1342-1751 (ISSN-L)
  • 1437-7799
OpenAlex
W2912114494
Cited by
83
References
110
Citations by year
2026: 2 · 2025: 3 · 2024: 16 · 2023: 14 · 2022: 24 · 2021: 14 · 2020: 9 · 2019: 1
FWCI
9.23
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Clinical and Experimental Nephrology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
  • Leicester Research Archive (University of Leicester) (submittedVersion, cc-by)
Funders
National Institute for Health and Care Research (CL-2016-11-002, ACF-2015-11-005)
Topics
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
Keywords
IgA nephropathy, primary glomerulonephritis, renal replacement therapy, risk stratification, treatment response prediction, disease management strategies, diagnosis
MeSH terms
Animals, Glomerulonephritis, IGA, Humans, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New strategies and perspectives on managing IgA nephropathy. https://app.cochat.ai/papers/10.1007/s10157-019-01700-1
The paper
Selvaskandan, H., Cheung, C. K., Muto, M., & Barratt, J. (2019). New strategies and perspectives on managing IgA nephropathy. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-019-01700-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.